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INTRODUCTION: Mesenchymal stem cells 
(MSC) harvested from human bone marrow show 
great promise for therapeutic interventions. The 
relatively easy isolation protocol, the high 
proliferation capacity and their ability to 
differentiate into different cell types of the 
mesenchyme puts them into primary focus of 
regenerative medicine.1 Insertion of targeted DNA 
into MSCs gives raise to new therapeutic 
strategies. The phenotype of intervertebral disc 
(IVD) cells is still obscured. Recent evidence 
demonstrated that growth and differentiation factor 
5 (GDF-5) is a promising cytokine pushing stromal 
progenitor cells possibly towards a disc-like 
phenotype.2,3 The aim of this study was to transfect 
MSCs with a plasmid containing the full open 
reading frame (ORF) of GDF-5. The procedure 
included a combination of electroporation 
(nucleofection) and sub-sequent lipofection with 
the aim to differentiate MSCs to IVD cells with the 
over-expression of GDF-5. Nucleofection is a 
straightforward method to insert genes of interest 
into target cells without the need of silenced 
viruses, which are not well accepted as therapeutic 
vectors.4. 
METHODS: MSCs were harvested from bone 
marrow aspirations of 4 patients undergoing spine 
surgery and isolated through histopaque density 
centrifugation and plastic adhesion (Ethical permit 
#187/10 of ethical authorities of the canton of 
Bern). These isolated cells were cultured and 
expanded for 2 weeks and then transfected with a 
GFP-tagged ORF clone of the GDF-5 gene by 
nucleofection using the nucleofector from Amaxa 
(Lonza, Basel, Switzerland). In addition, 
lipofection (Invitrogen, Basel, Switzerland) was 
applied and the cells were analyzed for RT-PCR, 
immunohistochemistry over time to see the effect 
of the GDF-5 transfection. 
 
RESULTS: Increased levels of GDF-5 gene 
expression by nucleofected-MSC were confirmed 
using RT-PCR (Figure 1). We found ACAN 
upregulated but not collagen type 2. GDF-5 
specific antibody confirmed presence of 
intracellular GDF-5 compared to untransfected 
control cells by immunohistochemistry. 
Fig. 1 Gene expression of MSC nucleofected with 
plasmid GDF-5 and encapsulated in alginate. 
Expression levels were adjusted to control cells. 
Per gene 3 time-points (colorized bars) were 
monitored: from left to right day 7, day 14, day 21. 
Gray bars correspond to day 0 (day 7 in 
monolayer culture). Bars represent min to max 
with a line at the mean. N=4). 
 
DISCUSSION & CONCLUSIONS: These results 
suggest that gene delivery by nucleofection of 
GDF-5 is an attractive approach for the release of 
GDF-5, which was produced by the cells 
themselves. Previous studies point towards an 
IVD-relevant role of GDF-5 to rescue IVD 
degeneration. Future studies will have to 
demonstrate longevity of the over-expression of 
GDF-5 in vitro and in vivo. Injection of transfected 
MSCs into 3D organ culture will show 
performance of cells in the IVD environment. Non-
viral gene therapy seems a more promising 
approach from a translational medicine perspective 
than viral methods.4 
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